GSK to use Owlstone’s breath biopsy in COPD trial

27th November 2017 Uncategorised 0

In a major boon for UK diagnostics group Owlstone Medical, GlaxoSmithKline is incorporating the firm’s Breath Biopsy platform into the clinical development programme for its novel, experimental respiratory drug danirixin.

More: GSK to use Owlstone’s breath biopsy in COPD trial
Source: News